1. Home
  2. GPGI vs PRAX Comparison

GPGI vs PRAX Comparison

Compare GPGI & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GPGI

GPGI Inc.

N/A

Current Price

$23.61

Market Cap

7.2B

Sector

N/A

ML Signal

N/A

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$330.00

Market Cap

8.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GPGI
PRAX
Founded
2000
2015
Country
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.2B
8.6B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GPGI
PRAX
Price
$23.61
$330.00
Analyst Decision
Strong Buy
Analyst Count
0
15
Target Price
N/A
$519.60
AVG Volume (30 Days)
2.2M
494.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
0.04%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$12.53
N/A
Revenue Next Year
$9.95
$38,343.63
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.24
$26.70
52 Week High
$26.78
$335.75

Technical Indicators

Market Signals
Indicator
GPGI
PRAX
Relative Strength Index (RSI) 42.60 60.92
Support Level $21.60 $314.35
Resistance Level $25.66 $335.75
Average True Range (ATR) 1.28 15.86
MACD 0.01 -0.33
Stochastic Oscillator 49.51 87.81

Price Performance

Historical Comparison
GPGI
PRAX

About GPGI GPGI Inc.

GPGI Inc is a diversified holding platform comprising businesses operating in multiple industries. The platform focuses on acquiring, owning, and scaling operating companies. It currently includes CompoSecure and Husky Technologies. CompoSecure provides technology and manufacturing solutions related to metal payment cards, security, and authentication. Its products and services are used by financial institutions, fintech companies, and other customers. Husky designs and manufactures industrial equipment and provides aftermarket services. Its equipment is used in the production of plastic products, including beverage and food containers, medical devices, and consumer electronics components.

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

Share on Social Networks: